Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury
- 660 Downloads
To evaluate safety in an interim analysis of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in 13 patients with hepatic metastases from neuroendocrine tumors (NETs) as part of a phase II trial.
Institutional Review Board approval and informed consent were obtained. Thirteen patients completed preliminary safety analysis. Their mean age was 65 years, Eastern Cooperative Oncology Group status was 0/1, tumor burden range was 4–75 %, and mean targeted tumor size was 5.9 cm. Up to four DEB-TACE sessions (100–300 μm beads loaded with ≤100 mg doxorubicin) within 6 months were allowed. Tumor response was assessed by magnetic resonance imaging 1 month after treatment using contrast-enhancement [European Association for the Study of the Liver (EASL) and size Response Evaluation Criteria in Solid Tumors (RECIST)] criteria. Safety was assessed by National Cancer Institute Common Terminology Criteria.
DEB-TACE was successfully performed in all 13 patients. At 1 month follow-up, there was a mean 12 % decrease in tumor size (p < 0.0003) and a 56 % decrease in tumor enhancement (p < 0.0001). By EASL criteria, the targeted lesion objective response rate was 78 %. Grade 3 to 4 toxicities were fatigue (23 %), increased alanine amino transferase (15 %), hyperglycemia (15 %), and abdominal pain (8 %). Seven patients developed bilomas (54 %); all of these patients had multiple small (<4 cm) lesions. Subsequently, four underwent percutaneous drainage, three for abscess formation and one for symptoms related to mass effect.
Although biloma and liver abscess are known risks after TACE, the high incidence in our study population was unexpected and forced interruption of the trial. Although this occurred in a small group of patients, we have changed our technique and patient selection as a result of these findings, thus allowing resumption of the trial.
KeywordsBiliary injury Chemoembolization Drug-eluting beads Neuroendocrine metastases
This study was partially funded by National Institutes of Health Grant No. R01 CA160771-2 and BioCompatibles UK Ltd. Clinical Trials.gov trial no. NCT00730483. Previous presentations include the following: (1) American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, San Francisco, CA, January 20 to 22, 2011; (2) Cardiovascular and Interventional Radiological Society of Europe, 2011, Sept 10–14, and (3) Society of Interventional Radiology, 36th Annual Scientific Meeting, Chicago, IL, 2011.
Conflict of interest
Nikhil Bhagat, Mingde Lin, and Jean-Francois Geschwind were partially funded by National Institutes of Health Grant No. R01 CA 160771-2. Jean-Francois Geschwind was partially funded by Biocompatibles UK Ltd.
- 6.Mayo SC, de Jong MC, Pawlik TM (2011) Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer. Ann Surg Oncol 18(53):S220–221Google Scholar
- 26.Gasnier A et al. (2010) In: IEEE international symposium on biomedical imaging: from nano to macro, Austin, TX, USA, 13–18 June 2010Google Scholar
- 27.Mory B et al. (2009) Non-Euclidean image-adaptive radial basis functions for 3D interactive segmentation. In: Twelfth IEEE international conference on computer vision (ICCV), Kyoto, JapanGoogle Scholar
- 38.Lencioni R et al. (2011) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol, October 2011. [Epub ahead of print]Google Scholar